GLTO
Closed
Galecto inc
3.41
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.41
Day's Range: 3.2801 - 3.65
Send
sign up or login to leave a comment!
When Written:
2.05
Galecto Inc. is a clinical-stage biotechnology company that develops novel therapies for fibrosis and cancer. The company was founded in 2011 and is headquartered in Copenhagen, Denmark, with additional offices in Boston, Massachusetts, and Montreal, Canada. Galecto's lead drug candidate, GB0139, is a galectin-3 inhibitor that is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. The company also has a pipeline of other galectin inhibitors for the treatment of fibrosis and cancer, including GB1211 for myelofibrosis and GB2064 for pancreatic cancer. Galecto has raised over $300 million in funding from investors, including Novo Holdings, Morningside Ventures, OrbiMed Advisors, and Ysios Capital.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!